We have located links that may give you full text access.
GlycA, a composite low-grade inflammatory marker, predicts mortality: prime time for utilization?
Journal of Internal Medicine 2019 July 16
Inflammation is a common mechanism in many chronic diseases, including cancer and cardiovascular disease. Numerous studies have shown that high-sensitivity C-reactive protein (hsCRP), one of the most frequently studied inflammatory markers, is associated with chronic inflammatory-related disease, cardiovascular disease, cancer and mortality [1]. While hs-CRP is a single marker of inflammation, GlycA is a composite biomarker that reflects the glycosylation states of several of the most abundant acute-phase proteins [2]. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app